Navigation Links
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
Date:6/9/2009

ts in glucose tolerance and insulin sensitivity
  • Significant reduction in plasma glucose levels in extremely hyperglycemic animals
  • No harmful effects such as low blood glucose levels (hypoglycemia) or detrimental changes in kidney function with 3-6 month exposure in normal or diabetic animals.

  • "Our preclinical research during the past year on ISIS-SGLT2Rx extends previous findings and demonstrates potent and sustained reduction of blood glucose levels with good safety and tolerability in multiple animal models including non-human primates. Collectively, the data suggest that ISIS-SGLT2Rx could result in sustained and significant reductions in blood glucose levels in diabetic patients and could be used as an infrequent injectable drug to help control blood sugar. This year, we have initiated our first clinical trial on ISIS-SGLT2Rx that will not only assess the safety of the drug in healthy volunteers, but may also provide us with information on the activity of the drug by measuring the effect of ISIS-SGLT2Rx on glucose excretion in urine. We are excited to continue to move this drug forward through development," said Sanjay Bhanot, M.D., Ph.D., Vice President of Metabolic Disorders and Head of Translational Medicine at Isis Pharmaceuticals.

    Isis scientists presented new data demonstrating that antisense reduction of retinal binding protein 4 (RBP4) caused significant improvements in insulin sensitivity with associated improvement in cardiac glucose metabolism. These data suggest that RBP4 could be an important new therapeutic target for type 2 diabetes and associated cardiac disease.

    In addition to new data demonstrating the ability of antisense drugs to significantly improve insulin sensitivity in diabetic animals, Isis also presented data from its obesity drug discovery program. In an oral presentation, Isis reported that antisense reduct
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
    3. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
    4. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
    5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
    6. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
    7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
    8. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
    9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
    10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
    11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
    (Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
    (Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
    Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
    ... May 21, 2007/PRNewswire-FirstCall/ -- Bristol-Myers,Squibb Company (NYSE: ... which showed that treatment with Baraclude (entecavir),demonstrated ... 48 weeks,-- a result that was also ... These data from an open-label, randomized viral ...
    ... -- Data presented,today at a major medical meeting ... for five days is as,effective as standard therapy ... treatment of complicated urinary tract infections,(cUTI) and acute ... markets LEVAQUIN in the,U.S., presented the data during ...
    Cached Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4
    (Date:12/21/2014)... (PRWEB) December 21, 2014 SCI ... of the issues and systemic barriers for disabled athletes ... Paratriathlon Champion. Scheidies has a condition called juvenile macular ... He describes how he adapted his athletic ambitions to ... his success in triathlon to pioneer the way for ...
    (Date:12/21/2014)... Columbus, OH (PRWEB) December 21, 2014 ... of men alleging heart attacks, stroke and blood clots ... continue to increase, a new study shows that the ... developing colon cancer. In a study published in the ... lead researcher, James Amos-Landgraf examined a group of male ...
    (Date:12/21/2014)... December 21, 2014 The Oncology Institute of ... the Santa Ana and Whittier offices. The Hope for the ... lives of patients and their families during the holiday season. ... to approximately 70 children between both offices. This event continues ... of Target’s community service team, store managers and assistant managers ...
    (Date:12/20/2014)... BambooIndustry.com is a professional company offering many ... recently shown its new engineered bamboo flooring collection, and ... models. , BambooIndustry.com’s customers come from many countries in ... to the CEO of the company, the global bamboo ... past few years, and the demand for eco-friendly bamboo ...
    (Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just done ... drastically cut prices to all its prom dresses already, ... 2015. Many of the hottest styles are sold here ... and more. , A spokesman for MissyDress says, “The ... princess prom dresses or sweetheart chiffon prom dresses, you ...
    Breaking Medicine News(10 mins):Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
    ... THURSDAY, Sept. 16 (HealthDay News) -- When it comes to ... cryotherapy -- works better than applying salicylic acid, another common ... cured more than half of cases, however, and better treatments ... The new finding is a bit of an about-face, according ...
    ... In a paper appearing in the Sept. 16 online ... professor of biology and member of the David H. ... researchers at Harvard University report a previously unknown element ... can trigger an alternative biochemical pathway that speeds up ...
    ... the Robert Wood Johnson Foundation Initiative on the Future of ... a blueprint for using nurse-led models of innovation to improve ... former Health and Human Services Secretary and University of Miami ... Officer at Cedars-Sinai Medical Center in Los Angeles Linda Burnes ...
    ... the environmental trigger that initiates and perpetuates chronic intestinal ... bowel disease (IBD), a study led by Harvard School ... bowel disease results from a loss of homeostasis, or ... inhabit the intestine. "In this study, we identified two ...
    ... our cells can divide is dictated by telomeres, stretches of ... keep our chromosomes and by extension, our genomes ... fields of both aging and cancer. Now, scientists at The ... structure and function of a crucial domain in the protein ...
    ... intensive care patients develop post-traumatic stress syndrome (PTSD) after ... is thought to be exacerbated by delusional or fragmentary ... Now researchers writing in BioMed Central,s open access journal ... and close relatives make a diary for patients, featuring ...
    Cached Medicine News:Health News:For Common Warts, Freezing Therapy Works Best: Study 2Health News:For Common Warts, Freezing Therapy Works Best: Study 3Health News:MIT researchers discover an unexpected twist in cancer metabolism 2Health News:MIT researchers discover an unexpected twist in cancer metabolism 3Health News:Ways nursing can advance health care improvements: IOM to hold briefing on Oct. 5 2Health News:Bacteria identified that may lead to inflammatory bowel disease in certain individuals 2Health News:Protein clamps tight to telomeres to help prevent aging ... and support cancer 2Health News:Protein clamps tight to telomeres to help prevent aging ... and support cancer 3Health News:Intensive care diaries protect patients from PTSD 2
    ... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
    ... The PACHETT 3 uses the exact enhanced ... the DGH pachymeters used exclusively by the ... built into the software. The new backlit ... running average, standard deviation and IOP correction ...
    ... Already, the most advanced motor driven ... easier and faster to learn and operate. ... maintaining accuracy and precision. Our software makes ... easy transition from manual instruments or other ...
    The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
    Medicine Products: